Literature DB >> 22534407

Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.

Natalia S Rost1, Eric E Smith, Muhammad A Pervez, Philip Mello, Paul Dreyer, Lee H Schwamm.   

Abstract

BACKGROUND: We sought to determine if intravenous tissue plasminogen activator (IV tPA) use for acute ischemic stroke increased in Massachusetts in association with the Primary Stroke Service program, a statewide stroke center designation and quality improvement initiative. METHODS AND
RESULTS: We analyzed prospectively acquired data from the Massachusetts Department of Public Health between October 2004 and June 2008, including 10 045 consecutive emergency department-based acute ischemic stroke encounters arriving ≤ 3 hours after stroke onset at 69 participating Massachusetts PSS hospitals. The overall rate of IV tPA use was 854 of 3866 (22.1%) of patients arriving ≤ 2 hours of symptom onset. IV tPA use increased steadily from 2005 (the first full year of the program) to 2008 (18.4%, 21.9%, 22.6%, 25.5%; P=0.001). Patients treated with IV tPA were more likely to be younger (72.3 ± 14.1 versus 74.7 ± 14.0 years, P<0.005) and to have presented after emergency medical services rerouting in July 2005 (96% versus 94%, P=0.009). Patients who arrived at hospitals with a performance achievement award from the Get With The Guidelines-Stroke program were more likely to receive IV tPA after versus before award recognition (28.1% versus 22.3%, P<0.001).
CONCLUSIONS: In this nearly complete capture of statewide data, rates of IV tPA improved significantly in Massachusetts from 2005 to 2008 in association with a state Primary Stroke Service designation program. Further studies are needed to confirm that treatment disparities exist for older acute ischemic stroke patients and that the rates of thrombolysis have increased above and beyond secular trends.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534407      PMCID: PMC3361890          DOI: 10.1161/CIRCOUTCOMES.111.962829

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  27 in total

1.  Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.

Authors:  Opeolu Adeoye; Richard Hornung; Pooja Khatri; Dawn Kleindorfer
Journal:  Stroke       Date:  2011-06-02       Impact factor: 7.914

2.  Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience.

Authors:  D Tanne; M J Gorman; V E Bates; S E Kasner; P Scott; P Verro; J R Binder; J M Dayno; L R Schultz; S R Levine
Journal:  Stroke       Date:  2000-02       Impact factor: 7.914

3.  Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke.

Authors:  Gregg C Fonarow; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Xin Zhao; Dai Wai Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-02-22

4.  Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002.

Authors:  Brian T Bateman; H Christian Schumacher; Bernadette Boden-Albala; Mitchell F Berman; J P Mohr; Ralph L Sacco; John Pile-Spellman
Journal:  Stroke       Date:  2006-01-05       Impact factor: 7.914

5.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

Authors:  Kennedy R Lees; Erich Bluhmki; Rüdiger von Kummer; Thomas G Brott; Danilo Toni; James C Grotta; Gregory W Albers; Markku Kaste; John R Marler; Scott A Hamilton; Barbara C Tilley; Stephen M Davis; Geoffrey A Donnan; Werner Hacke; Kathryn Allen; Jochen Mau; Dieter Meier; Gregory del Zoppo; D A De Silva; K S Butcher; M W Parsons; P A Barber; C Levi; C Bladin; G Byrnes
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

6.  Prioritizing interventions to improve rates of thrombolysis for ischemic stroke.

Authors: 
Journal:  Neurology       Date:  2005-02-22       Impact factor: 9.910

7.  Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients.

Authors:  Jörg Berrouschot; Joachim Röther; Jörg Glahn; Thomas Kucinski; Jens Fiehler; Götz Thomalla
Journal:  Stroke       Date:  2005-10-06       Impact factor: 7.914

8.  Translating evidence into practice: a decade of efforts by the American Heart Association/American Stroke Association to reduce death and disability due to stroke: a presidential advisory from the American Heart Association/American Stroke Association.

Authors:  Lee Schwamm; Pierre Fayad; Joseph E Acker; Pamela Duncan; Gregg C Fonarow; Meighan Girgus; Larry B Goldstein; Tammy Gregory; Margaret Kelly-Hayes; Ralph L Sacco; Jeffrey L Saver; Wendy Segrest; Penelope Solis; Clyde W Yancy
Journal:  Stroke       Date:  2010-02-24       Impact factor: 7.914

Review 9.  Prehospital care of the acute stroke patient.

Authors:  Venkatakrishna Rajajee; Jeffrey Saver
Journal:  Tech Vasc Interv Radiol       Date:  2005-06

10.  Quality of care and outcomes in patients with diabetes hospitalized with ischemic stroke: findings from Get With the Guidelines-Stroke.

Authors:  Mathew J Reeves; Robert S Vaidya; Gregg C Fonarow; Li Liang; Eric E Smith; Robert Matulonis; DaiWai M Olson; Lee H Schwamm
Journal:  Stroke       Date:  2010-03-11       Impact factor: 7.914

View more
  15 in total

Review 1.  Hyperacute management of ischemic stroke.

Authors:  Sarah Song
Journal:  Semin Neurol       Date:  2014-02-06       Impact factor: 3.420

Review 2.  Development of regional stroke programs.

Authors:  Adam de Havenon; Ali Sultan-Qurraie; Peter Hannon; David Tirschwell
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

3.  Telestroke in an urban setting.

Authors:  Shawna Cutting; James J Conners; Vivien H Lee; Sarah Song; Shyam Prabhakaran
Journal:  Telemed J E Health       Date:  2014-06-26       Impact factor: 3.536

4.  Improving thrombolysis for acute ischemic stroke in Lombardia stroke centers.

Authors:  A Cavallini; E Tartara; S Marcheselli; E Agostoni; S Quaglini; G Micieli
Journal:  Neurol Sci       Date:  2013-02-08       Impact factor: 3.307

5.  Thrombolytic utilization for ischemic stroke in US hospitals with neurology residency program.

Authors:  Yogesh Moradiya; Howard Crystal; Helen Valsamis; Steven R Levine
Journal:  Neurology       Date:  2013-11-01       Impact factor: 9.910

6.  Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers.

Authors:  Hugo J Aparicio; Brendan G Carr; Scott E Kasner; Michael J Kallan; Karen C Albright; Dawn O Kleindorfer; Michael T Mullen
Journal:  J Am Heart Assoc       Date:  2015-10-14       Impact factor: 5.501

7.  The Relationships Among Regionalization, Processes, and Outcomes for Stroke Care: A Nationwide Population-based Study.

Authors:  Yu-Chi Tung; Guann-Ming Chang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

8.  Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.

Authors:  Steven R Messé; Pooja Khatri; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Deepak L Bhatt; Maria V Grau-Sepulveda; Margueritte Cox; Eric D Peterson; Gregg C Fonarow; Lee H Schwamm
Journal:  Neurology       Date:  2016-09-14       Impact factor: 9.910

9.  When in rome, do like the Romans: certifying stroke centers with the rod of aesculapius or the medical caduceus of hermes?

Authors:  Lee H Schwamm
Journal:  J Am Heart Assoc       Date:  2013-04-04       Impact factor: 5.501

10.  Demographic Disparities in Proximity to Certified Stroke Care in the United States.

Authors:  Cathy Y Yu; Timothy Blaine; Peter D Panagos; Akash P Kansagra
Journal:  Stroke       Date:  2021-06-10       Impact factor: 10.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.